Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant
NCT03354728
Recruiting
This phase I/II trial studies the side effects and best dose of multi-antigen cytomegalovirus (CMV)-modified vaccinia ankara vaccine and to see how well it works in treating pediatric patients with positive cytomegalovirus who are undergoing donor stem cell transplant. Multi-antigen CMV-modified vaccinia ankara vaccine may help people resist CMV life-threatening complications.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
10/01/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Cytomegaloviral Infection, Hematopoietic Cell Transplant Recipient
Register for Updates
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas
NCT04917861
Completed
This clinical study will evaluate the safety, tolerability, and reactogenicity of 2 dose levels of messenger RNA (mRNA)-1893 Zika vaccine in comparison to a placebo control in healthy participants who are flavivirus-seronegative and in participants who are flavivirus-seropositive.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/27/2024
Locations: Meridian Clinical Research (Sioux City, IA), Sioux City, Iowa +10 locations
Conditions: Zika Virus
Register for Updates
COVID-19 Protection After Transplant Pilot Study
NCT04969263
Completed
Antibodies are an important part of the body's defense against infection. Individuals who have no antibodies or very low antibody levels are considered less well protected from Coronavirus Disease 2019 (COVID-19) than those who have higher antibody levels. What level of antibodies is necessary for protection is currently unknown. Inadequate antibody response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination has been described among kidney transplant recipients. The aim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Kidney Transplant Recipients
Register for Updates
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults
NCT05297578
Completed
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 65 years of age and older.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
09/26/2024
Locations: Accel Research Sites-Birmingham Clinical Research Unit, Birmingham, Alabama +19 locations
Conditions: Pneumococcal Vaccines
Register for Updates
H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses
NCT02921997
Completed
This is a single center, randomized, partially-blinded, Phase II, small, targeted, prospective study in approximately 30 healthy male and non-pregnant female subjects aged 18 to 49 years old, inclusive, designed to evaluate and compare the immunogenicity between an intramuscular monovalent inactivated influenza A/H7N9 virus vaccine given with and without AS03 adjuvant, and an intramuscular unadjuvanted monovalent inactivated influenza A/H3N2v virus vaccine. The primary objectives are (1) assessi... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
09/26/2024
Locations: Vanderbilt University Medical Center - Vanderbilt Institute for Clinical and Translational Research - Clinical Research Center (VICTR-CRC), Nashville, Tennessee
Conditions: Avian Influenza, H1N1 Influenza, Influenza
Register for Updates
Vaccine Responses in Cancer
NCT06605625
Recruiting
The investigators are conducting a prospective unblinded study of individuals diagnosed with cancer who will receive one or more of the following: influenza, SARS-CoV2 and shingles.
Gender:
ALL
Ages:
All
Trial Updated:
09/25/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Viral Vaccines
Register for Updates
A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults
NCT05518500
Recruiting
This is a prospective, single-arm study designed to understand the mechanisms that lead to a loss of response to influenza vaccine in older adults. The investigators will recruit and longitudinally follow a cohort of 75 older adults (65 years and older) who will receive three different influenza vaccines over three annual influenza seasons. Blood samples will be collected from the participants at sixteen study visits over three years. Nasal swab and stool samples will also be collected from part... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
09/17/2024
Locations: UConn Health, Center On Aging, Farmington, Connecticut
Conditions: Aging, Influenza Vaccine, Dendritic Cell, Vaccine Response
Register for Updates
Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults
NCT06151288
Completed
The objective of the study is to evaluate the safety, tolerability and immunogenicity of a single injection of VAX-31 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 50 to 64 years of age in Stage 1. Stage 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-31 at 3 dose levels compared to PCV20 in adults aged 50 years and older.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
09/16/2024
Locations: AMR Mobile, Mobile, Alabama +24 locations
Conditions: Pneumococcal Vaccines
Register for Updates
Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)
NCT05158140
Completed
The purpose of this study is to evaluate the concomitant and non-concomitant use of messenger ribonucleic acid (mRNA) mRNA-1273, the nucleoside-modified mRNA vaccine for active immunization to prevent coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), with a 23-valent pneumococcal polysaccharide vaccine (V110) for the prevention of pneumococcal disease, or a 15-valent pneumococcal conjugate vaccine (V114) indicated for the prevention of invasive... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
09/11/2024
Locations: Carbon Health ( Site 0045), North Hollywood, California +45 locations
Conditions: Pneumococcal Infection
Register for Updates
Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients
NCT04922944
Completed
This research study is studying how healthcare worker recipients react after receiving vaccinations for COVID-19. The objective of the study is to evaluate the immune response to COVID-19 vaccination. The immunity will be evaluated over time by measuring serum semi-quantitative SARS-Co-V2 IgG from blood specimens and analyzing vaccine reaction data. SARS-CoV-2 is the name for the virus responsible for COVID-19 infections. IgG, immunoglobulin G, is an antibody found in the blood that protects aga... Read More
Gender:
ALL
Ages:
All
Trial Updated:
09/11/2024
Locations: Huntington Hospital, Pasadena, California
Conditions: Covid19, Vaccine Reaction
Register for Updates
BCG Vaccine for Health Care Workers as Defense Against COVID 19
NCT04348370
Completed
SARS-CoV-2 spreads rapidly throughout the world. A large epidemic would seriously challenge the available hospital capacity, and this would be augmented by infection of healthcare workers (HCW). Strategies to prevent infection and disease severity of HCW are, therefore, desperately needed to safeguard continuous patient care. Bacille Calmette-Guérin (BCG) is a vaccine against tuberculosis, with protective non-specific effects against other respiratory tract infections in in vitro and in vivo stu... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/11/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California +5 locations
Conditions: Coronavirus, Coronavirus Infection, Coronavirus as the Cause of Diseases Classified Elsewhere
Register for Updates
A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.
NCT05873751
Completed
Brief Summary: The main purpose of the study is to learn about how well Trumenba vaccine shot works against gonorrhea infection. This study looks at data records from a database in the United States. This study includes patient's data from the database who: * Are 15-30 years old. * Have received at least one dose of Trumenba and a MenACWY vaccine or who have received only MenACWY vaccine. This data has already been collected in the past and is being studied between April and June of 2023.
Gender:
ALL
Ages:
Between 15 years and 30 years
Trial Updated:
09/09/2024
Locations: Pfizer, New York, New York
Conditions: Gonorrhea, Chlamydia, Meningococcal Vaccines
Register for Updates